Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Mugaba

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Vaccine|March 3, 2015
Frequencies of Gag-restricted T-cell escape "footprints" differ across HIV-1 clades A1 and D chronically infected Ugandans irrespective of host HLA B allelesJennifer Serwanga, Ritah Nakiboneka, Susan Mugaba, et al.
Plos One|June 10, 2011
Coreceptor and cytokine concentrations may not explain differences in disease progression observed in HIV-1 clade A and D infected UgandansEdward Wright, Susan Mugaba, Paul Grant, et al.
Vaccine|November 22, 2018
Interferon gamma (IFN-γ) negative CD4+ and CD8+ T-cells can produce immune mediators in response to viral antigensRitah Nakiboneka, Susan Mugaba, Betty O Auma, et al.
AIDS Research and Treatment|April 15, 2011
CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI SubstudyJennifer Serwanga, Susan Mugaba, Auma Betty, et al.
AIDS Research and Human Retroviruses|August 27, 2011
Profile of T cell recognition of HIV type 1 consensus group M Gag and Nef peptides in a clade A1- and D-infected Ugandan populationJennifer Serwanga, Susan Mugaba, Edward Pimego, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 18, 2025
Validation of high-throughput oxford nanopore technology for HIV-1 transmitted/founder virus identificationDrake Byamukama, Christian Ndekezi, Denis Omara, et al.
Virology Journal|March 18, 2026
Evolutionary dynamics of HIV-1 recombinants: analysis of contemporary and historical viral populations in East AfricaSheila N Balinda, Anne Kapaata, Frank Kato, et al.
Frontiers in Immunology|February 15, 2024
Sustained S-IgG and S-IgA antibodies to Moderna's mRNA-1273 vaccine in a Sub-Saharan African cohort suggests need for booster timing reconsiderationsJennifer Serwanga, Violet Ankunda, Joseph Ssebwana Katende, et al.
Frontiers in Immunology|May 19, 2023
Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policyJennifer Serwanga, Claire Baine, Susan Mugaba, et al.
Plos One|May 20, 2026
Practical guidelines for producing non-replicating canine adenovirus vectorsDenis Omara, Christian Ndekezi, Susan Mugaba, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Vaccine|March 3, 2015
Frequencies of Gag-restricted T-cell escape "footprints" differ across HIV-1 clades A1 and D chronically infected Ugandans irrespective of host HLA B allelesJennifer Serwanga, Ritah Nakiboneka, Susan Mugaba, et al.
Plos One|June 10, 2011
Coreceptor and cytokine concentrations may not explain differences in disease progression observed in HIV-1 clade A and D infected UgandansEdward Wright, Susan Mugaba, Paul Grant, et al.
Vaccine|November 22, 2018
Interferon gamma (IFN-γ) negative CD4+ and CD8+ T-cells can produce immune mediators in response to viral antigensRitah Nakiboneka, Susan Mugaba, Betty O Auma, et al.
AIDS Research and Treatment|April 15, 2011
CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI SubstudyJennifer Serwanga, Susan Mugaba, Auma Betty, et al.
AIDS Research and Human Retroviruses|August 27, 2011
Profile of T cell recognition of HIV type 1 consensus group M Gag and Nef peptides in a clade A1- and D-infected Ugandan populationJennifer Serwanga, Susan Mugaba, Edward Pimego, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 18, 2025
Validation of high-throughput oxford nanopore technology for HIV-1 transmitted/founder virus identificationDrake Byamukama, Christian Ndekezi, Denis Omara, et al.
Virology Journal|March 18, 2026
Evolutionary dynamics of HIV-1 recombinants: analysis of contemporary and historical viral populations in East AfricaSheila N Balinda, Anne Kapaata, Frank Kato, et al.
Frontiers in Immunology|February 15, 2024
Sustained S-IgG and S-IgA antibodies to Moderna's mRNA-1273 vaccine in a Sub-Saharan African cohort suggests need for booster timing reconsiderationsJennifer Serwanga, Violet Ankunda, Joseph Ssebwana Katende, et al.
Frontiers in Immunology|May 19, 2023
Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policyJennifer Serwanga, Claire Baine, Susan Mugaba, et al.
Plos One|May 20, 2026
Practical guidelines for producing non-replicating canine adenovirus vectorsDenis Omara, Christian Ndekezi, Susan Mugaba, et al.
Pageof 3